August 22, 2024 /
Boster's MS Corner
CLICK image to watch this video
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- People Wait an Average of 50 Days to See a Neurologist, and People with MS Wait Even Longer: What Can We Do to Improve Access to MS Care?
- Key Findings on GLP-1 Use in MS
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
- Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
- This Blood Test Tracks MS Activity? (Octave Explained)
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
- Will Medicare Pay for a Mobility Scooter?
- Vagus nerve stimulation (VNS)
- Vitamin D Deficiency in Adults: Symptoms, Treatments, and Related Health Conditions
- How to Get Through an MRI if You’re Claustrophobic
- How MS Can Affect Your Oral Health
- Signs of multiple sclerosis show up in blood years before symptoms, study finds
- MS patients less likely to have Alzheimer’s, study finds
- APOE4 gene variant linked to greater nerve damage in MS: Study
- High Epstein-Barr antibody levels over time may aid MS diagnosis
- Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds
- Online Survey: Stress and MS – from the National MS Society
- High-Altitude Gene Helps Heal Myelin Damage
- Talking Biosimilars – Unlocking Patient access through coordinated action
- Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.
